Filing excerpt
Received FDA full approval for Tecartus in adult patients with R/R mantle cell lymphoma, following an accelerated approval in this setting in July 2020.
Source: Autobound Signal API · 74 signals tracked for Gilead · updated
Get Gilead's live signals in Claude or ChatGPT, or by API
What changed at Gilead this week? Use Autobound signals for gilead.com.Gilead received FDA full approval for Tecartus in adult patients with relapsed or refractory mantle cell lymphoma, converting an accelerated approval from July 2020. Commercial expansion of cell therapy portfolios often leads to investments in specialized supply chain tracking, apheresis logistics, and healthcare provider onboarding platforms.
Filing excerpt
Received FDA full approval for Tecartus in adult patients with R/R mantle cell lymphoma, following an accelerated approval in this setting in July 2020.
What this signalsFilings often name leadership changes, deals and spending plans.
Technologies
Regions named
sec-10qproductLaunchGet every 10-Q signal for Gilead and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Gilead this week?”
The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/08ae073d-d884-4dd2-a6ad-0adec7f88297 returns this record as JSON. POST /v1/companies/enrich returns every signal for gilead.com.
{
"signal_id": "08ae073d-d884-4dd2-a6ad-0adec7f88297",
"signal_type": "sec-10q",
"signal_subtype": "productLaunch",
"detected_at": "2026-11-09T06:32:59.422+00:00",
"company": {
"name": "Gilead",
"domain": "gilead.com"
},
"data": {
"detail": "Gilead received FDA full approval for Tecartus in adult patients with relapsed or refractory mantle cell lymphoma, converting an accelerated approval from July 2020. Commercial expansion of cell therapy portfolios often leads to investments in specialized supply chain tracking, apheresis logistics, and healthcare provider onboarding platforms.",
"metrics": {
"timeframe": "current_quarter"
},
"quarter": "Q2",
"summary": "FDA grants full approval for Tecartus in R/R mantle cell lymphoma",
"excerpts": "Received FDA full approval for Tecartus in adult patients with R/R mantle cell lymphoma, following an accelerated approval in this setting in July 2020.",
"relevance": 0.8,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/882095/000088209526000031/gild-20260630.htm",
"filing_date": "2026-08-06",
"filing_year": 2026,
"fiscal_year": 2026,
"fiscal_year_end": "06/30",
"period_end_date": "2026-06-30",
"sales_relevance": "Go-to-market support",
"signal_category": "strategic",
"regions_mentioned": [
"U.S."
],
"technologies_mentioned": [
"CAR T-cell"
]
}
}
curl https://signals.autobound.ai/v1/signals/08ae073d-d884-4dd2-a6ad-0adec7f88297 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"gilead.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.